Showing 2011-2020 of 3314 results for "".
- NIH-Led Team Sets New Bar in Retinal Imaginghttps://modernod.com/news/nih-led-team-sets-new-bar-in-retinal-imaging/2478963/A team led by scientists at the National Eye Institute (NEI) has noninvasively visualized the light-sensing cells in the back of the eye, known as photoreceptors, in greater detail than ever before. Published in Optica, the researchers report how they improved imaging resolution by a thi
- ASCRS Introduces Richard L. Lindstrom Lecture for 2021 Annual Meetinghttps://modernod.com/news/ascrs-introduces-richard-l-lindstrom-lecture-for-2021-annual-meeting/2478960/The American Society of Cataract and Refractive Surgery (ASCRS) has announced the inaugural Richard L. Lindstrom Lecture and Medal, which will be delivered along with other distinguished lectures at the 2021 ASCRS Annual Meeting in Las Vegas, Nevada. The Richard L. Lindstrom Lecture and Me
- Lilly’s Bamlanivimab, Etesevimab Cut Hospitalizations, Deaths in High-Risk COVID-19 Patientshttps://modernod.com/news/lillys-bamlanivimab-etesevimab-cut-hospitalizations-deaths-in-high-risk-covid-19-patients/2478961/Eli Lilly reported new phase 3 results demonstrating that the antibody cocktail containing bamlanivimab and etesevimab significantly reduced COVID-19-related hospitalizations and deaths in high-risk patients recently diagnosed with SARS-CoV-2 infection. “These positive results reinforce our
- Santen EMEA Leads Awareness Campaign to Prioritize Their Glaucoma During the Pandemichttps://modernod.com/news/santen-emea-leads-awareness-campaign-to-prioritize-their-glaucoma-during-the-pandemic/2478942/Santen, along with a group of patient advocacy groups across Europe, is leading a multi-channel awareness campaign to encourage patients to prioritize their glaucoma during the pandemic. The on-and-offline campaign, w
- PYC’s Lead Investigational Drug, VP-001, Demonstrates Another Key Functional Improvement in Patient-Derived Modelshttps://modernod.com/news/pycs-lead-investigational-drug-vp-001-demonstrates-another-key-functional-improvement-in-patient-derived-models/2478930/PYC Therapeutics announced that the company’s lead investigational drug, VP-001, for the treatment of RP11 has restored function of the retinal pigment epithelium (RPE), the target cells for the therapy, in patient-derived models of the disease. “This result builds further conviction in VP
- Lexitas Announces George N. Magrath, MD, MBA Assumes Role of Chief Executive Officerhttps://modernod.com/news/lexitas-announces-george-n-magrath-md-mba-assumes-role-of-chief-executive-officer/2478905/George N. Magrath, MD, MBA, MS, has been named CEO of Lexitas Pharma Services. Chad Ice will transition from the role as CEO to President with a focus on strategic growth initiatives as well as the expansion of the Lexitas Board of Directors. These changes became effective February 1, 2021. <
- Essilor Mourns Passing of Bernard Maitenaz, Inventor of the First Varilux Progressive Lenshttps://modernod.com/news/essilor-mourns-passing-of-bernard-maitenaz-inventor-of-the-first-varilux-progressive-lens/2478895/Essilor announced that Bernard Maitenaz, the inventor of the Varilux progressive lens that improved the lives of millions of presbyopes globally and redefined an entire industry, has passed away in his home city of Paris at the age of 94. Bernard Maitenaz’s pioneering work revolutionized
- Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Gel, 0.5%https://modernod.com/news/akorn-receives-fda-approval-for-loteprednol-etabonate-ophthalmic-gel-0-5/2478864/Akorn announced that it received approval of its abbreviated new drug application (ANDA) from the FDA for loteprednol etabonate ophthalmic gel, 0.5%, which is indicated for the treatment of postoperative inflammation and pain following ocular surgery. “We are excited to launch yet an
- FDA Clears Lilly’s COVID-19 Antibody Duo Bamlanivimab, Etesevimab for Emergency Usehttps://modernod.com/news/fda-clears-lillys-covid-19-antibody-duo-bamlanivimab-etesevimab-for-emergency-use/2478854/Eli Lilly said Tuesday that it received FDA emergency-use authorization (EUA) for a neutralizing antibody cocktail combining bamlanivimab with etesevimab to treat mild-to-moderate COVID-19 in patients 12 and older who are at high risk for progressing to severe disease and/or hospitalization. Acco
- Euclid Systems Announces Expansion of Leadership Teamhttps://modernod.com/news/euclid-systems-announces-expansion-of-leadership-team/2478845/Euclid Systems has announced expansion of its leadership team. Joseph Boorady, OD, FAAO, appointed to the position of president and chief executive officer in January 2020, brings over 25 years of experience in the ophthalmic industry as an eye care professional, educational leader, entrepreneur